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Introduction
The design of delivery systems able to selectively release en-
trapped guests in the presence of target molecules is a new re-
search field that has recently attracted great attention.
[1] Tradi-
tional delivery systems are based on organic polymers that
usually release their cargo through diffusion-controlled pro-
cesses or degradation of the polymeric matrix.
[2] As an alterna-
tive, in recent years, silica mesoporous supports have been
used as inorganic scaffolds for the storage and controlled re-
lease of drugs and organic molecules. The unique properties
of mesoporous silica materials, such as the presence of or-
dered tailor-made mesopores with stable structures, large sur-
face areas, bio-compatibility and the possibility to include
gate-like scaffoldings on the external surface for the design of
nanodevices for on-command delivery applications, make
these solids suitable supports for the development of carriers
for cargo delivery.
[3] In these systems, mass transport can be
controlled using molecular and supramolecular interactions or
suitable physical stimuli.
[4] In particular, delivery of the cargo in
gated materials have been reported using changes in pH,
[5]
temperature,
[6] redox potential,
[3d,7] light,
[8] and the presence of
small molecules.
[9] However, despite these interesting exam-
ples, some of the described systems show disadvantages for
their potential use in advanced applications, such as a lack of
function in aqueous environments and the use of complex
The synthesis of capped mesoporous silica nanoparticles (MSN)
conjugated with an antibody (AB) as a gatekeeper has been
carried out in order to obtain a delivery system able to release
an entrapped cargo (dye) in the presence of a target molecule
(antigen) to which the conjugated antibody binds selectively.
In particular, MSN loaded with rhodamine B and functionalized
on the external surface with a suitable derivative of N-(t-butyl)-
3-oxo-(5a,17b)-4-aza-androst-1-ene-17-carboxamide (finaste-
ride) have been prepared (S1). The addition of polyclonal anti-
bodies against finasteride induced capping of the pores due to
the interaction with the anchored hapten-like finasteride deriv-
ative to give a MSN–hapten–AB nanoparticle S1-AB.I tw a s
found that the addition of capped material S1-AB to water sol-
utions containing finasteride resulted in displacement of the
antibody, pore uncapping and entrapped-dye release. The re-
sponse of the gated material is highly selective, and only finas-
teride, among other steroids, was able to induce a significant
uncapping process. Compared with finasteride, the finasteride
metabolite was able to release 17% of the dye, whereas the
exogen steroids testosterone, metenolone and 16-b-hydroxy-
stanozolol only induced very little release of rhodamine B
(lower than 10%) from aqueous suspensions containing sens-
ing solid S1-AB. A detection limit as low as 20 ppb was found
for the fluorimetric detection of finasteride. In order to evalu-
ate a possible application of the material for label-free detec-
tion of finasteride, the capped material was isolated and
stored to give final sensing solid S1-AB-i. It was found to dis-
play a similar behavior towards finasteride as to that shown by
freshly prepared S1-AB; even after a period of two months, no
significant loss of selectivity or sensitivity was noted. Moreover,
to study the application for the detection of finasteride in bio-
logical samples, this “aged” material, S1-AB-i, was tested using
commercially available blank urine as matrix. Samples contain-
ing 70 and 90% blank urine were spiked with a defined
amount of finasteride, and the concentration was determined
using capped S1-AB-i. Recovery ranges from 94% to 118%
were reached.
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trolled guest release in response to small molecules or biomol-
ecules are still very rare. One of the most frequently used
types of biomolecules for the development of gated hybrid
materials are enzymes. The wide collection of available en-
zymes that can selectively catalyze a large number of different
chemical reactions makes these systems very appealing for the
design of sensitive and specific mesoporous silica nanoparti-
cles (MSN)-based nanodevices.
[10] Also, in this field we and
others have reported the use of oligonucleotides for the
design of gated MSN for delivery applications.
[11]
Furthermore, it is apparent from the literature that most of
the reported gated materials have been designed toward the
development of advanced drug-delivery systems, but very few
examples of pore-blockage or pore-opening protocols for sens-
ing applications have been reported.
[9] However, the design of
such systems able to respond to the presence of target mole-
cules is an attractive approach for the development of new
sensing paradigms. The protocol involves the use of selective
molecular recognition events that control the gate-like scaf-
folding. The addition of the solid to a solution containing the
target molecule induces pore opening and delivery of a suita-
ble dye. If the opening and dye release is a consequence of
a selective interaction, the recognition event is translated into
a selective optical response. This approach separates the rec-
ognition protocols from the signaling event making sensing in-
dependent of the stoichiometry of the host–guest complex
and, in some cases, simultaneously displaying features of
signal amplification.
Given our interest in the development of advanced bio-in-
spired strategies on inorganic materials for sensing applica-
tions using biomolecules, we recently combined the use of an-
tigen–antibody interactions with the preparation of capped
MSN able to selectively deliver an entrapped dye in the pres-
ence of sulfathiazole.
[12] In particular, we believe that the use of
antibodies could be a promising approach for the design of
custom-made nanodevices for controlled delivery specifically
triggered by target guests. The possibility of selecting antibod-
ies for a countless number of antigens, including low molecu-
lar weight targets, makes this approach highly appealing for
a wide range of applications. Additionally, this approach opens
the possibility of developing novel label-free immunoassay
paradigms in which the properties of the reporter (cargo)
could be selected at will. Inspired by these previous results, we
report herein the preparation of antibody-capped MSN for the
selective fluorogenic signaling of finasteride, a substance used
in sport doping.
Results and Discussion
Design and synthesis of gated MSN
The incorporation of gate-like ensembles on mesoporous scaf-
folds has proven to be a suitable approach for the develop-
ment of nanoscopic solids for mass-transport control and for
studying the factors that could influence the design of gating
functions. Additionally, as stated above, very few examples
have been reported that use capped materials for the design
of new sensing concepts. Moreover, in this particular field, the
use of antibodies or other biomolecules as “biological keys”
opens a wide range of possible opportunities for the design of
new sensing protocols. In this study, we selected MSN from
the MCM-41 family as the support. This is a suitable inorganic
matrix that displays several appropriate characteristics, such as
homogeneous porosity, high inertness and ease of functionali-
sation. Moreover, MCM-41 materials usually contain mesopores
in the 2–3 nm range, which allows a rapid uptake and release
of selected guests.
We focused our attention on the potential detection of fi-
nasteride, a 5a-reductase inhibitor. Finasteride is known to
convert testosterone to the more potent androgen 5a-dihy-
drotestosterone, a class of drug that is used therapeutically to
prevent prostate cancer, treat benign prostatic hyperplasia and
male baldness. It has been reported that administration of in-
hibitors of 5a-reductase, such as finasteride, can complicate
the evaluation of steroid profiles in sport doping control, caus-
ing erroneous results. The reason lies in the suppression of
production and renal excretion of 5a-reduced metabolites of
anabolic steroids that can produce false-negative doping-con-
trol results. In a previous work, an enzyme-linked immunosorb-
ent assay for the detection of finasteride was reported.
[13] In
this work, a collection of immunoreagents and antiserum were
obtained from which we selected the best hapten–antiserum
pair for the development of an antibody-capped mesoporous
hybrid nanomaterial for the fluorimetric detection of finaste-
ride (see below).
Scheme 1 shows the proposed paradigm using the gated
support. Nanoparticles of mesoporous MCM-41 are first loaded
with a fluorophore (rhodamine B), then, the external surfaces
of the nanoparticles are functionalized with hapten-like deriva-
tive 2 to give solid S1. Finally the mesopores are capped with
finasteride antibodies (AB) via interactions of the two binding
IgG regions of the antibody with anchored 2, giving solid S1-
AB. Addition of the correspondent antigen, finasteride, induces
uncapping of the pores and release of the entrapped fluoro-
phore. The uncapping process is easily monitored by measur-
ing the emission intensity of rhodamine B at 580 nm (lex=
555 nm) in the aqueous phase.
For the preparation of solid S1, the hapten-like molecule
1 was selected. Capped materials obtained from 1 (via anchor-
age of silyl derivative 2) proved to give a suitable response in
terms of time and sensitivity (see below). Compound 2 was
readily obtained through reaction of 1 with (3-aminopropyl)-
triethoxysilane. To prepare the final hybrid material S1,w e
made use of a two-step synthetic procedure. First, the meso-
porous starting scaffold was added to a solution containing
a high concentration of rhodamine B in order to reach an effi-
cient loading of the pores. Second, organosilane derivative 2
was added. During the grafting of 2, a high concentration of
rhodamine B was contained in the solution, which inhibits dif-
fusion of the dye from the pores into the solution and simulta-
neously hampers the entrance of 2 into the pores. Moreover, it
has been reported that the reaction of organosilane derivatives
with siliceous surfaces is usually quicker than diffusion process-
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[9a–c] These features lead to the reasonable
assumption that rhodamine B is captured within the meso-
pores and derivative 2 is anchored on the external surface of
the final nanoparticles. Purple solid S1 was isolated by filtra-
tion, washed with acetonitrile and dried at 358C for 12 h. Solid
S2 containing rhodamine B within the pores, but lacking deriv-
ative 2 was also prepared as a control.
Capping optimization with the specific polyclonal antibodies
for finasteride was carried out by stirring solid S1 (1 mg) for
one hour in different aqueous dilutions of serum I (0.5 mL,
pH 7.4; dilutions of 2.5:100, 1.25:100, 0.625:100 or 0.3125:100).
After the capping process, the aqueous phase was removed by
centrifugation, and the solid was washed twice to remove re-
sidual dye from the uncapped pores. The final material was
suspended in water (0.025 mgmL
 1; pH 7.4), and the kinetic re-
lease of rhodamine B was measured by monitoring the fluores-
cence emission at 580 nm (lex=555 nm). The most effective
capping was observed with a 1.25:100 dilution of serum I.
Lower proportions of serum showed only partial capping of
the pores, which was reflected in significant rhodamine B re-
lease.
Characterization of the hybrid materials
The prepared solids were characterized using standard tech-
niques. Figure 1 shows powder X-ray diffraction (PXRD) pat-
terns of synthesized MCM-41, calcined MCM-41, and S1. The
PXRD of synthesized, siliceous nanoparticulated MCM-41 (Fig-
ure 1a) shows the typical four low-angle reflections attributed
to a hexagonal array that index as (100), (110), (200), and (210)
Bragg peaks. From the PXRD data of synthesized MCM-41,
a d100 spacing of 40.93   was calculated. A significant displace-
ment of the (100) peak in the PXRD of the calcined
nanoparticulated MCM-41 was found corresponding
to an approximate cell contraction of 2   (Figure 1b).
This displacement and broadening of the (110) and
(200) peaks are related to further condensation of si-
lanol groups during the calcination step. Figure 1c
shows the PXRD patterns for solid S1. In this curve,
the reflections (110) and (200) are less intense, most
likely due to a reduction in contrast as a consequence
of the pore loading with the dye and the functionali-
zation with derivative 2. Nevertheless, the clear pres-
ence of the (100) peak in the PXRD patterns indicates
that the process of pore loading with rhodamine B
and the additional functionalization with 2 did not
modify the mesoporous structure of the MCM-41
support to a large extent.
The mesoporous structure of the functionalized
solid S1 and in the capped material S1-AB of the
mesoporous structure was also confirmed using
transmission electron microscopy (TEM) analysis. The
synthesized MCM-41 support was obtained as spheri-
cal particles with diameters ranging from 80 to
150 nm. Figure 2 shows TEM images for S1 and S1-
AB. In both cases, the typical hexagonal porosity and
channels of the MCM-41 matrix as alternate black and white
stripes are observed.
The N2 adsorption–desorption isotherm of the calcined
nanoparticulated MCM-41 is shown in Figure 3a. A typical
curve for mesoporous solids consisting of an adsorption step
at intermediate P/P0 values (0.25–0.4) is observed. This curve
Figure 1. Powder X-ray patterns of the solids a) MCM-41, b) calcined MCM-
41 and c) solid S1 containing rhodamine B and compound 2.
Scheme 1. Representation of gated material S1-AB capped with an antibody, compounds
1 and 2 and the antigen, finasteride.
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indicates nitrogen condensation inside the mesopores. In the
solids, the existence of uniform cylindrical mesopores—pore
diameter of 2.62 nm and pore volume of 0.88 cm
3g
 1, calculat-
ed using the Barret, Joyner and Halenda (BJH) model on the
adsorption branch of the isotherm—is suggested by the ab-
sence of a hysteresis loop in this interval and the narrow BJH
pore distribution (Table 1). The application of the Brunauer,
Emmett and Teller (BET) model resulted in a value of
1053.4 m
2g
 1 for the total specific surface. From the PXRD, po-
rosimetry and TEM studies, the a0 cell parameter (4.57 nm),
pore diameter (2.62 nm), and value for the wall thickness
(1.95 nm) were calculated. In addition to this adsorption step
associated to the micelle generated mesopores, a second fea-
ture appears in the isotherm at a high relative pressure (P/P0>
0.85). This adsorption corresponds to the filling of the large
voids among the particles (pore diameter of 36.4 nm and pore
volume of 0.42 cm
3g
 1, calculated by using the BJH model)
and therefore must be considered as a textural-like porosity.
The N2 adsorption–desorption isotherm of S1 is shown in Fig-
ure 3b. Solid S1 presents a similar adsorption–desorption iso-
therm to the one observed with calcined MCM-41. However,
the specific surface and pore volume of S1 is reduced by
~50%, that is, a BJH mesopore volume of 0.44 cm
3g
 1 and sur-
face area of 625.2 m
2g
 1 were calculated. This decrease in
volume of adsorbed N2 and in pore size is ascribed to the pres-
ence of the dye and anchored derivative 2 on the external sur-
face of S1. The moderate decrease on the specific surface area
and pore volume in S1 is most likely due to the fact that the
pores are not completely closed. Additionally, the textural po-
rosity is preserved strongly suggesting that dye molecules are
placed inside the mesopores and not in the interparticle poros-
ity.
As described above, the transformation of S1 to S1-AB by
the addition of antibody does not significantly alter the struc-
tural order of the mesoporous support based on TEM images
of this solid. Unfortunately, it was not possible to carry out ad-
ditional PXRD or N2 adsorption–desorption studies on S1-AB
due to the small amount of material prepared. However, de-
spite this lack of complete characterization, the behavior of S1-
AB is fully consistent with the capping–uncapping procedure
described in Scheme 1 (see below).
The quantity of derivative 2 and dye in S1 and dye in S2
was determined by elemental analysis and thermogravimetric
studies. The thermal analysis of S1 and S2 shows a typical be-
havior of functionalized mesoporous materials, that is, an initial
weight loss between 25 and 1508C related to solvent evapora-
tion, a second loss between 150 and 8008C due to the com-
bustion of organic material, and a final loss in the 800–10008C
range related to the condensation of the silanol groups. The
dye content in solid S1-AB was determined from the difference
between the amount measured for S1 and the amount re-
leased into the aqueous washing fractions of the solid after in-
teraction with the antibody (Table 2).
With the aim of estimating the amount of antibody in solid
S1-AB, concentrations of immunoglobulin G (IgG, the most
Figure 2. Transmission electron microscopy (TEM) images of a) solid S1-AB,
b) solid S1 and c) and d) calcined MCM-41 sample showing the typical hex-
agonal porosity of the MCM-41 mesoporous matrix.
Figure 3. Adsorption–desorption isotherms for a) MCM-41 and b) dye-loaded
and functionalized S1. Inset: Pore-size distribution of MCM-41.
Table 1. Brunauer, Emmett and Teller (BET)-specific surface values, pore
volumes and pore sizes.
[a]
Solid SBET [m
2 g
 1] Pore volume [cm
3 g
 1] Pore size [nm]
MCM-41 1053.4 0.88 2.62
S1 625.2 0.44 2.33
[a] Calculated from N2 adsorption–desorption isotherms.
Table 2. Concentration [mmolg
 1] of compound 2, rhodamine B and IgG
in solids S1, S1-AB and S2.
Solid Compd 2 Rhodamine B IgG
S1 0.275 0.389 –
S1-AB 0.275 0.298 0.0001926
S2 – 0.403 –
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serum I and in the aqueous solutions after the capping process
by measuring the absorbance at 280 nm. Considering an aver-
age molecular weight (MW) of 150 kDa and the specific molar
extinction coefficient of immunoglobulin, a concentration in
serum I of 5.3 mgmL
 1 was found. Taking into account the ab-
sorbance measurements, an estimated 87% of the antibodies
were incorporated in S1-AB when a serum dilution of 1.25:100
was used. With this data and the known concentration of IgG
in serum I, it can be estimated that one gram of S1-AB con-
tains 1.16 10
17 immunoglobulin molecules. Additionally, con-
sidering the typical external surface of an MCM-41 support, an
average distance between two immunoglobulin molecules of
~17 nm is calculated (for details, see the Supporting Informa-
tion). The amounts of compound 2, antibody and rhodamine B
in S1, S1-AB and S2 are shown in Table 2.
Functional antigen-driven controlled release
Several experiments were carried out in order to study the an-
tigen-responsive controlled-release protocol using capped ma-
terial S1-AB and finasteride as a trigger. The uncapping proto-
col, that is, the delivery of the entrapped dye from the pore
voids to the aqueous solution, was observed with ease by
monitoring the emission band of rhodamine B centered at
580 nm (lex=555 nm) in the aqueous phase. In a typical ex-
periment, a suspension of S1-AB (0.2 mL, 2 mgmL
 ) was dilut-
ed with water (9.8 mL, pH 7.4) containing finasteride
(130 ppm). A corresponding experiment was carried out under
similar conditions using S1-AB but in the absence of finaste-
ride. At a given time point, 1 mL of each suspension was fil-
tered, and the emission of rhodamine B was measured at
580 nm.
From the kinetic-release curves shown in Figure 4, it can be
seen that solid S1-AB was unable to release rhodamine B in
the absence of finasteride, whereas in the presence of the anti-
gen a remarkable delivery of the dye was found (cf. Figure 4a
and b). In this case, maximum delivery of dye was achieved
after approximately 15 min. The release of rhodamine B was
a direct consequence of the displacement process of the anti-
body from the outer surface of S1-AB induced by the presence
of free finasteride. The observed uncapping process is caused
by the stronger interaction of finasteride with the capping an-
tibody compared with the interaction of the antibody and
grafted 2. In fact, when the same experiment is repeated in
the presence of compound 1 instead of finasteride, only 23%
dye release is observed (compared with the amount of dye re-
leased in the presence of finasteride, i.e., 100%).
Similar kinetic experiments with S1-AB using lower amounts
of finasteride were carried out. In those cases, a lower amount
of dye was released (rhodamine B delivery was proportional to
the concentration, see below), and overall slower delivery ki-
netics were found. Finally, a release time of 75 min was select-
ed for further experiments in order to reach a maximum dye
delivery for all tested finasteride concentrations.
Figure 5 shows the fluorescence intensity of rhodamine B re-
leased from solid S1-AB measured in water (pH 7.4) as a func-
tion of the concentration of finasteride. The delivered amount
of cargo is proportional to finasteride concentration displaying
a typical noncompetitive immunoassay response curve, which
is in accordance with an uncapping protocol based on the dis-
placement of the antibody, as indicated above. From these
studies, a detection limit for finasteride of 20 ppb was calculat-
ed.
Selectivity studies
It is well-known that antibodies can ideally identify and bind
only to their unique antigen in complex mixtures. This proper-
Figure 4. Fluorescence intensity over time of released rhodamine B at
580 nm (lex=555 nm) from S1-AB in water (pH 7.4) a) in the absence and
b) in presence of of finasteride (130 ppm). The inset shows the fluorescence
spectra of the rhodamine B-containing solution after filtration a) in absence
and b) in presence of finasteride after 2 min. Fluorescence was measured
after filtration (0.45 mm teflon filters). A photograph visualizes the colorimet-
ric response.
Figure 5. Fluorescence intensity of rhodamine B released from solid S1-AB
measured at 580 nm (lex=555 nm) in water (pH 7.4) as a function of finas-
teride concentration after an incubation period of 75 min. Fluorescence was
measured after filtration (0.45 mm teflon filters). The inset shows rhodami-
ne B release in the low finasteride concentration range.
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can ideally be opened using a unique “molecular key”. In order
to investigate the selectivity in the opening protocol of our
system, dye delivery from solid S1-AB was tested in the pres-
ence of other exogen steroids that produce similar effects to fi-
nasteride. The uncapping ability of these closely related mole-
cules (at 1 ppm) is shown in Figure 6, which displays the fluo-
rescence of the released dye from S1-AB after 75 min in the
presence of the steroids finasteride, finasteride metabolite, tes-
tosterone, metenolone, 16-b-hydroxystanozolol, dutasteride,
oxandrolone, 1-testosterone, androstanolone, or testosterone
glucuronide (for chemical structures, see the Supporting Infor-
mation). A very selective uncapping process in the presence of
finasteride was observed. Only finasteride metabolite is able to
release 17% of the dye (relative to finasteride), whereas the
exogen steroids testosterone, metenolone and 16-b-hydroxy-
stanozolol induced a very small release of rhodamine B (lower
than 10%) from aqueous suspensions of the sensing solid
S1-AB.
In addition to these delivery studies with S1-AB, further con-
trol experiments were carried out using solid S2, in order to
evaluate the effect on the selective delivery process of the
anchored hapten. Unlike S1-AB, solid S2 contains rhodamine B
in its mesopores but does not have any additional functionali-
zation. Aqueous suspensions of solid S2 (pH 7.5) alone showed
a fast dye release. However in the presence of antibody, dye
delivery was strongly inhibited due to unspecific adsorption of
the antibody onto the surface of S2, most likely through inter-
actions with the silanol groups on the silica mesoporous sup-
ports (SMPS). Very importantly, the addition of finasteride to
S2-AB did not lead to cargo delivery, even when large
amounts of finasteride were added (up to 200 ppm).
Storage of sensing material and assays with urine standard
In order to improve the properties of S1-AB for a potential ap-
plication in the detection of finasteride, we tried to isolate and
store solid S1-AB. The final sensing material (S1-AB-i) was pre-
pared from S1-AB, which was further dried in vacuo overnight
and then stored at 48C. It was found that, even after a period
of two months, stored solid S1-AB-i showed a similar sensing
behavior toward finasteride as that shown by freshly prepared
S1-AB without significant loss of selectivity or sensitivity.
Moreover, in order to study the possible application in the
detection of finasteride in biological samples, S1-AB-i was
tested using commercially available blank urine as matrix. In
a first step, the tolerance of the solids to urine was studied. In
a typical experiment, S1-AB-i (0.45 mg) was suspended in
urine (5 mL), and the suspension was then diluted with varying
amounts of water (pH 7.4). Following this procedure, calibra-
tion curves for finasteride containing 50, 70 and 90% urine
were obtained, and a similar linear range for all three tested di-
lutions was found. Moreover, it was confirmed that the results
using solid S1-AB-i were similar to those obtained for S1-AB.
In a second step, urine samples containing 70 and 90% urine
were spiked with finasteride, and the concentrations were de-
termined using the previously obtained calibration curve. The
results found are shown in Table 3. Target analyte spike recov-
eries in the range of 94–118% were achieved.
Conclusion
In summary, the use of antibodies as gatekeepers on the sur-
face of MSN provides a suitable tool for the design of delivery
systems able to release entrapped guests in the presence of
target molecules (antigen) to which an antibody binds selec-
tively. In this work, we prepared MSN loaded with rhodamine B
and functionalized with a suitable derivative of finasteride on
their external surface. Addition of polyclonal antibodies for fi-
nasteride induced the capping of the pores due to the interac-
tion with the anchored hapten-like derivative. This material
was used for the fluorimetric recognition of finasteride and is
one of the few examples that use a capped system and open-
ing protocols for chemosensing applications. It was found that
addition of the capped material to water solutions containing
Figure 6. Relative fluorescence intensity of rhodamine B released from
S1-AB was measured at 580 nm (lex=555 nm) in water (pH 7.4) in presence
of exogen steroids finasteride, finasteride metabolite, testosterone, meteno-
lone, 16-b-hydroxystanozolol, dutasteride, 1-testosterone, androstanolone
(DHT), oxandrolone, or testosterone glucuronide (1 ppm). Fluorescence was
measured after filtration (0.45 mm teflon filters).
Table 3. Finasteride concentrations [ppb] in samples containing 70% and
90% urine determined using solid S1-AB-i.
Urine Finasteride Recovery
[%] added found [%]
70 33.3 35.57 2.56 106.7
70 66.6 62.92 2.03 94.4
90 30 35.38 1.17 117.9
90 60 58.57 1.84 97.6
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ping of the pores and release of the entrapped dye. The re-
sponse of this gated material is highly selective, and only finas-
teride, among other steroids, was able to trigger dye delivery.
A detection limit as low as 20 ppb was found for the fluorimet-
ric detection of finasteride. Although this detection limit is
higher than the value obtained using an enzyme-linked immu-
nosorbent assay (ELISA, 0.01 ppb),
[13] we believe that gated
SMPS based on the use of antibodies could be a promising
route for the development of custom-made, controlled-deliv-
ery nanodevices specifically triggered by target molecular
guests. The possibility of including antibodies as caps on di-
verse supports, the choice of the cargo molecule (e.g., various
dyes and fluorophores), and the potential design of nanoparti-
cles containing two or more different loaded signaling mole-
cules capped with their corresponding antibodies open the
door to the design of new multiplex label-free immunoassay
protocols. Further studies in this field are ongoing. It is impor-
tant to note that the use of capped nanoparticles introduces
two remarkable advantages into the immunoassay developed
format. One is the direct displayed response, which means that
increasing the target concentration in samples results in an in-
crease of the analytical signal. Secondly, for this format it is not
necessary to synthesize the typical tracers used in ELISA or
other immunoassay-labeled formats. In a wider context, this
work suggests that the combination of SMPS with suitable
binding sites is an excellent starting point for applying the ver-
satility of supramolecular ideas to the design of nanoscopic de-
vices, which is a promising approach for bringing molecular
and supramolecular concepts to new advances in the field of
nanoscience.
Experimental Section
General techniques
Powder X-ray diffraction (PXRD) and thermogravimetric analysis
(TGA), elemental analysis, transmission electron microscopy (TEM),
N2 adsorption–desorption, NMR, UV–visible (UV–vis) and fluores-
cence spectroscopy were employed to characterize the synthesized
materials. PXRD measurements were performed on a D8 Advance
diffractometer using Cu Ka radiation (Philips, Amsterdam, The
Netherlands). Thermogravimetric analyses were carried out on
a TGA/SDTA 851e balance (Mettler Toledo, Columbus, OH, USA),
using an oxidizing atmosphere (air, 80 mLmin
 1) with a heating
program: gradient of 393!1273 K at 108Cmin
 1, followed by an
isothermal heating step at 12738C for 30 min. TEM images were
obtained with a 100 kV CM10 microscope (Philips). N2 adsorption–
desorption isotherms were recorded with an ASAP2010 automated
sorption analyzer (Micromeritics, Norcross, GA, USA). The samples
were degassed at 1208C in vacuo overnight. The specific surface
areas were calculated from the adsorption data in the low pressure
range using the Brunauer, Emmett and Teller (BET) model. Pore
size was determined following the Barret, Joyner and Halenda
(BJH) method.
1H and
13C NMR spectra were acquired with a Varian
300 spectrometer (Sunnyvale, CA, USA). UV–vis spectroscopy was
carried out using a Lambda 35 spectrometer (PerkinElmer Instru-
ments, Waltham, MA, USA). Fluorescence spectroscopy was carried
out on a Felix 32 Analysis version 1.2 (Build 56, Photon Technology
International, Birmingham, NJ, USA). The polyclonal-based antibod-
ies for finasteride were obtained according to Ref. [13].
Chemicals
Tetraethylorthosilicate (TEOS), N-cetyltrimethylammonium bromide
(CTABr), NaOH, (3-aminopropyl)triethoxysilane, rhodamine B, finas-
teride, chemical reagents for hapten derivative synthesis (N,N’-dicy-
clohexylcarbodiimide and N-methylsuccinimide), bovine serum al-
bumin (BSA), complete and incomplete Freund’s adjuvant and
Tween 20 were purchased from Sigma–Aldrich Qu mica (Madrid,
Spain). Dutasteride was purchased from AK Scientific (Union City,
CA, USA). (5a-17b)-3-Oxo-4-aza-androst-1-ene-17-carboxylic acid (1)
was purchased from Steraloids Inc. (Newport, USA). Keyhole limpet
hemocyanin (KLH) was purchased from Pierce Biotechnology
(Rockford, IL, USA). Phosphate-buffered saline (PBS, pH 7.4, 20 mm)
was prepared containing the following salts: Na2HPO4
(16.06 mmolL
 1), KH2PO4 (2.92 mmolL
 1), NaCl (274 mmolL
 1) and
KCl (5.46 mmolL
 1). PBS (20 mm) was supplemented with
Tween 20 (0.05%) to give Tween 20-containing PBS (PBST). All
products were used as received.
Synthesis
N-(3-triethoxysilyl(propyl))-3-oxo-(5a,17b)-4-aza-androst-1-ene-
17-carboxamide (2): A modification of the active ester method for
the amidation reaction between compound 1 and (3-aminopropyl)-
triethoxysilane was used.
[14] A mixture of N-hydroxysuccinimide
(NHS, 90.6 mg, 0.79 mmol) and N,N’-dicyclohexylcarbodiimide
(DCC, 162.4 mg, 0.79 mmol) in anhyd N,N-dimethylformamide
(DMF, 1.0 mL) was added to a solution of 1 (238.06 mg, 0.75 mmol)
in anhyd DMF (4 mL). The mixture was stirred at RT for 20 h, and
precipitated dicyclohexylurea (DCU, white solid) was removed by
centrifugation. (3-Aminopropyl)triethoxysilane (150 mL, 0.7 mmol)
was added to the solution, and the reaction mixture was stirred at
RT for 24 h. The solvent was evaporated in vacuo to give a yellow
sticky oil. In order to eliminate traces of DCU, CH2Cl2 (1 mL) was
added, and the solution was filtered through a short silica gel
column. The final product was isolated as a colorless oil (0.302 g,
0.58 mmol, 83%):
1H NMR (300 MHz, CDCl3): d=0.61 (t, 2H, CH2Si),
0.96 (s, 3H, CH3C), 1.21 (t, 9H, SiOCH2CH3), 1.24–2.11 (m, 22H), 3.25
(t, 2H, NHCH2CH2CH2Si), 3.80 (q, 6H, CH3CH2OSi), 5.78 (d, 1H,
COCH=CH), 6.78 ppm (d, 1H, COCH=CH);
13C NMR (75 MHz, CHCl3):
d=7.3 (CH2Si), 11.9 (CH3), 13.0 (CH2CH2Si) 13.3 (CH3), 18.2 (3C,
CH3CH2O), 21.1, 24.9, 25.6, 25.9, 29.4, 30.6, 33.8, 35.3, 36.2, 36.6,
39.4 (NHCH2CH2CH2Si), 48.8, 55.5, 58.2 (3C, CH3CH2O), 59.5, 122.9
(COCH=CH), 158.4 (COCH=CH), 164.9 (CONHCH), 173.7 ppm
(CONHCH2).
MCM-41 mesoporous nanoparticles: NaOH (2.00 molL
 1, 3.5 mL)
was added to a solution of CTABr (1.00 g, 2.74 mmol) in deionized
H2O (450 mL). After the solution temperature was adjusted to
808C, TEOS (5.00 mL, 2.57 10
 2 mol) was added dropwise to the
surfactant solution. The mixture was stirred for 2 h to give a white
precipitate. The solid was isolated by centrifugation and washed
with deionized H2O and EtOH (95:5) and then dried at 608C for
12h to give MCM-41. In order to remove the template phase,
MCM-41 was calcined at 5508C for 8h using an oxidizing atmos-
phere (air).
Solid S1: In a typical synthesis, calcined MCM-41 (0.3 g) and rho-
damine B (0.115 g, 0.24 mmol) were suspended in CH3CN (35 mL)
and heated at 1208C in a Dean–Stark apparatus to remove ad-
sorbed H2O by azeotropic distillation under an inert Ar atmos-
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24 h for loading of the MCM-41 pores. An excess of compound 2
(0.2 g, 0.384 mmol) in CHCl3 (0.5 mL) was added, and the final mix-
ture was stirred at RT for 5.5 h. Resulting solid S1 was isolated by
filtration, washed with CH3CN (10 mL) and dried at 388C for 12 h.
Solid S1-AB: In order to prepare solid S1–AB and study the inter-
actions between the anchored hapten 2 and the surface of solid
S1, and the specific polyclonal-based antibodies for finasteride,
portions of solid S1 (1 mg) were suspended in varying aq dilutions
of serum I (0.5 mL, pH 7.4; dilutions: 2.5:100, 1.25:100, 0.625:100,
and 0.3125:100). Each suspension was stirred at RT for 1 h. After
the capping process, the aq phase was removed by centrifugation
to eliminate residual dye and free antibody, and the concentration
of immunoglobulin (IgG) in the removed aq phase was measured.
Results are shown in Table 4. Taking into account the results shown
in Table 2, the ideal aq dilution for the preparation of the final ma-
terial S1-AB was 1.25:100 of serum I (pH 7.4). Lower concentrations
lead to incomplete pore capping, whereas higher concentrations
of serum I lead to complete pore capping and undesired antibody
adsorption.
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